This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Epic $12 billion deal and FDA's approval raise CAR-T to new heights. Nat Biotechnol 35, 891–892 (2017). https://doi.org/10.1038/nbt1017-891
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1017-891
This article is cited by
-
The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape
Nature Biotechnology (2020)
-
Evolution of CAR T-cell immunotherapy in terms of patenting activity
Nature Biotechnology (2019)
-
Allogene and Celularity move CAR-T therapy off the shelf
Nature Biotechnology (2018)
-
Reframing cell therapy for cancer
Nature Chemical Biology (2018)
-
Public biotech in 2017—the numbers
Nature Biotechnology (2018)